These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 35343254)

  • 21. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
    Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    Front Oncol; 2021; 11():835889. PubMed ID: 35174073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
    Zhu D; Ma K; Yang W; Zhou HF; Shi Q; Ren JW; Xie YG; Liu S; Shi HB; Zhou WZ
    Front Oncol; 2022; 12():1057560. PubMed ID: 36439471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
    Li N; Chen J
    Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
    Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
    Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
    Li J; Kong M; Yu G; Wang S; Shi Z; Han H; Lin Y; Shi J; Song J
    Front Immunol; 2023; 14():1188308. PubMed ID: 37545497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts.
    Ren Y; Sun B; Zhu L; Chen L; Sun T; Dong X; Zheng C
    Br J Radiol; 2024 Dec; 97(1164):1925-1930. PubMed ID: 39189936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
    Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
    AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
    [No Abstract]   [Full Text] [Related]  

  • 35. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for the Treatment of Advanced HBV-related Hepatocellular Carcinoma.
    Liu H; Yu Q; Gu T; Qu P; Ma X; Zhou S; Lu T; Pan D; Han Z
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):182-189. PubMed ID: 37345608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial chemoembolization using drug-eluting beads versus lipiodol in the treatment of unresectable hepatocellular carcinoma: propensity score matching.
    Cao G; Gu J; Zhang H; Ji W; Zhu D; Bao Y; Asi H; Ren W
    J Gastrointest Oncol; 2024 Jun; 15(3):1101-1111. PubMed ID: 38989437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Guo W; Chen S; Wu Z; Zhuang W; Yang J
    Technol Cancer Res Treat; 2020; 19():1533033820965587. PubMed ID: 33089769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.